Literature DB >> 15976068

Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.

Yasumasa Nishimura1, Kiyoshi Nakamatsu, Toru Shibata, Shuichi Kanamori, Ryuta Koike, Masahiko Okumura, Minoru Suzuki.   

Abstract

OBJECTIVE: Our aim was to evaluate predictors of xerostomia in patients with head and neck cancers treated with intensity-modulated radiation therapy (IMRT).
METHODS: Thirty-three patients with pharyngeal cancer were evaluated for xerostomia after having been treated with IMRT. All patients were treated with whole-neck irradiation of 46-50 Gy by IMRT, followed by boost IMRT to the high-risk clinical target volume to a total dose of 56-70 Gy in 28-35 fractions (median, 68 Gy). For boost IMRT, a second computed tomography (CT-2) scan was done in the third to fourth week of IMRT. Xerostomia was scored 3-4 months after the start of IMRT.
RESULTS: The mean doses to the contralateral and ipsilateral parotid glands were 24.0 +/- 6.2 and 30.3 +/- 6.6 Gy, respectively. Among the 33 patients, xerostomia of grades 0, 1, 2 and 3 was noted in one, 18, 12 and two patients, respectively. Although the mean dose to the parotid glands was not correlated with the grade of xerostomia, the initial volume of the parotid glands was correlated with the grade of xerostomia (P = 0.04). Of 17 patients with small parotid glands (< or =38.8 ml) on initial CT (CT-1), 11 (65%) showed grade 2 or grade 3 xerostomia, whereas only three (19%) of 16 patients with larger parotid glands showed grade 2 xerostomia (P < 0.05). The mean volume of the parotid glands on CT-1 was 43.1 +/- 15.2 ml, but decreased significantly to 32.0 +/- 11.4 ml (74%) on CT-2 (P < 0.0001).
CONCLUSIONS: Initial volumes of the parotid glands are significantly correlated with the grade of xerostomia in patients treated with IMRT. The volume of the parotid glands decreased significantly during the course of IMRT.

Entities:  

Mesh:

Year:  2005        PMID: 15976068     DOI: 10.1093/jjco/hyi108

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  16 in total

Review 1.  Assessment of post-radiotherapy salivary glands.

Authors:  S C H Cheng; V W C Wu; D L W Kwong; M T C Ying
Journal:  Br J Radiol       Date:  2011-05       Impact factor: 3.039

2.  Parotid gland-recovery after radiotherapy in the head and neck region--36 months follow-up of a prospective clinical study.

Authors:  Jeremias Hey; Juergen Setz; Reinhard Gerlach; Martin Janich; Guido Hildebrandt; Dirk Vordermark; Christian R Gernhardt; Thomas Kuhnt
Journal:  Radiat Oncol       Date:  2011-09-27       Impact factor: 3.481

Review 3.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

4.  Head and neck intensity modulated radiotherapy parotid glands: time of re-planning.

Authors:  Alba Fiorentino; Mariella Cozzolino; Rocchina Caivano; Piernicola Pedicini; Caterina Oliviero; Costanza Chiumento; Stefania Clemente; Vincenzo Fusco
Journal:  Radiol Med       Date:  2013-12-12       Impact factor: 3.469

Review 5.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-17       Impact factor: 3.603

6.  Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands.

Authors:  A Fiorentino; M Cozzolino; R Caivano; P Pedicini; C Chiumento; C Oliviero; S Clemente; V Fusco
Journal:  Clin Transl Oncol       Date:  2012-10-13       Impact factor: 3.405

7.  Analysis of factors influencing the development of xerostomia during intensity-modulated radiotherapy.

Authors:  Ken Randall; Jason Stevens; Juan Fernando Yepes; Marcus E Randall; Mahesh Kudrimoti; Jonathan Feddock; Jing Xi; Richard J Kryscio; Craig S Miller
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-03-22

8.  Parotid gland volumetric changes during intensity-modulated radiotherapy in head and neck cancer.

Authors:  A Fiorentino; R Caivano; V Metallo; C Chiumento; M Cozzolino; G Califano; S Clemente; P Pedicini; V Fusco
Journal:  Br J Radiol       Date:  2012-05-09       Impact factor: 3.039

9.  Predictive dose accumulation for HN adaptive radiotherapy.

Authors:  Donghoon Lee; Pengpeng Zhang; Saad Nadeem; Sadegh Alam; Jue Jiang; Amanda Caringi; Natasha Allgood; Michalis Aristophanous; James Mechalakos; Yu-Chi Hu
Journal:  Phys Med Biol       Date:  2020-11-27       Impact factor: 3.609

10.  The Long-Term Recovery of Parotid Glands in Nasopharyngeal Carcinoma Treated by Intensity-Modulated Radiotherapy.

Authors:  Shun Tasaka; Keiichi Jingu; Noriyoshi Takahashi; Rei Umezawa; Takaya Yamamoto; Yojiro Ishikawa; Kazuya Takeda; Yu Suzuki; Noriyuki Kadoya
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.